- Branwell International Limited Company News Section

Branwell International Limited Press Release -

  • Kymab Racing for a U.S. IPO Listing in 3rd Quarter of 2020.
  • Based in Cambridgeshire, Kymab is discovering and developing human monoclonal antibody therapeutics with an initial focus on malaria and HIV.
  • Led by CEO Simon Sturge, the pharmaceutical company has raised over 200m over seven funding rounds. Investors include LifeArc, Malin Corporation and ...
  • April 06, 2020